Sarcopenia defined by serum creatinine and cystatin C predicts poor survival outcomes in patients with cancers.
[BACKGROUND] The prognostic significance of sarcopenia estimated by serum creatinine and cystatin C in cancer patients remained inconsistent.
- 95% CI 1.42-2.06
- HR 1.71
- 연구 설계 meta-analysis
APA
Liu R, Wang J, et al. (2025). Sarcopenia defined by serum creatinine and cystatin C predicts poor survival outcomes in patients with cancers.. BMC geriatrics, 26(1), 93. https://doi.org/10.1186/s12877-025-06647-5
MLA
Liu R, et al.. "Sarcopenia defined by serum creatinine and cystatin C predicts poor survival outcomes in patients with cancers.." BMC geriatrics, vol. 26, no. 1, 2025, pp. 93.
PMID
41420155
Abstract
[BACKGROUND] The prognostic significance of sarcopenia estimated by serum creatinine and cystatin C in cancer patients remained inconsistent. The purpose of the meta-analysis was to comprehensively evaluate the association between creatinine/cystatin C ratio(CCR) or sarcopenia index(SI) and survival outcomes in cancer patients with sarcopenia.
[METHODS] A comprehensive search of relevant studies was implemented by scrutinizing Pubmed, Web of science and Embase databases until June 30, 2024. The pooled hazard ratios (HRs) with 95% confidence intervals (CIs) were used to evaluate the survival outcomes.
[RESULTS] 18 studies from 17 articles involving 9908 patients were enrolled in the study. The meta-analysis indicated that low CCR was significantly associated with poor overall survival (OS) (HR:1.71,95% CI: 1.42-2.06), progression free survival (PFS)((HR: 1.76; 95% CI: 1.33-2.34), recurrence free survival (RFS)(HR: 2.48; 95% CI: 1.52-4.05). Low SI was correlated with poor OS (HR: 1.60; 95% CI: 1.21-2.13). Subgroup analysis demonstrated that low CCR was an adverse prognostic marker not affected by cancer type, treatment method, country and analysis type.
[CONCLUSIONS] Sarcopenia assessed by CCR or SI predicted unfavorable prognosis in cancer patients. CCR or SI can be used as an effective and convenient indicator of sarcopenia in cancer patients.
[METHODS] A comprehensive search of relevant studies was implemented by scrutinizing Pubmed, Web of science and Embase databases until June 30, 2024. The pooled hazard ratios (HRs) with 95% confidence intervals (CIs) were used to evaluate the survival outcomes.
[RESULTS] 18 studies from 17 articles involving 9908 patients were enrolled in the study. The meta-analysis indicated that low CCR was significantly associated with poor overall survival (OS) (HR:1.71,95% CI: 1.42-2.06), progression free survival (PFS)((HR: 1.76; 95% CI: 1.33-2.34), recurrence free survival (RFS)(HR: 2.48; 95% CI: 1.52-4.05). Low SI was correlated with poor OS (HR: 1.60; 95% CI: 1.21-2.13). Subgroup analysis demonstrated that low CCR was an adverse prognostic marker not affected by cancer type, treatment method, country and analysis type.
[CONCLUSIONS] Sarcopenia assessed by CCR or SI predicted unfavorable prognosis in cancer patients. CCR or SI can be used as an effective and convenient indicator of sarcopenia in cancer patients.
MeSH Terms
Humans; Sarcopenia; Cystatin C; Neoplasms; Creatinine; Prognosis; Survival Rate; Biomarkers
같은 제1저자의 인용 많은 논문 (5)
- Editorial: Advancing NSCLC treatment: overcoming challenges in immune checkpoint inhibitor therapy.
- Mechanistic insights into the roles of astragalosides and polysaccharides in gynecological and breast cancers (Review).
- Recent research progress in structural optimization and cancer treatment of novel selective FGFR inhibitors (2020-2025).
- Predicting cervical lymph node metastasis in papillary thyroid carcinoma using capsule disruption length measured by 3D-US.
- Ginkgolic acid targets HSPA8 to trigger ferroptosis in hepatocellular carcinoma chaperone-mediated autophagy-dependent GPX4 degradation.